Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Liabilities (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Total Liabilities for 6 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 16.95% year-over-year to $21.3 million, compared with a TTM value of $21.3 million through Dec 2025, up 16.95%, and an annual FY2025 reading of $21.3 million, up 16.95% over the prior year.
  • Total Liabilities was $21.3 million for Q4 2025 at SAB Biotherapeutics, up from $18.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $42.6 million in Q4 2021 and bottomed at $7.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $19.0 million, with a median of $18.2 million recorded in 2023.
  • Peak annual rise in Total Liabilities hit 245.4% in 2022, while the deepest fall reached 53.4% in 2022.
  • Year by year, Total Liabilities stood at $42.6 million in 2021, then tumbled by 53.4% to $19.8 million in 2022, then soared by 34.24% to $26.6 million in 2023, then crashed by 31.59% to $18.2 million in 2024, then rose by 16.95% to $21.3 million in 2025.
  • Business Quant data shows Total Liabilities for SABS at $21.3 million in Q4 2025, $18.4 million in Q3 2025, and $18.1 million in Q2 2025.